As per DelveInsight’s assessment, about 40+ key pharma and biotech companies are working on 50+ drugs in the Sickle Cell Disease therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
Sickle Cell Disease Overview
Sickle cell disease encompasses a group of inherited conditions impacting red blood cells, with its most severe form known as sickle cell anemia. In individuals with this condition, sickle cells undergo rapid destruction, leading to anemia, a hallmark of sickle cell anemia. Additionally, these abnormally shaped cells obstruct blood flow in vessels, contributing to complications such as lung tissue damage, acute chest syndrome, pain crises, stroke, priapism, and organ damage to the spleen, kidneys, and liver. Despite being a lifelong and serious condition, long-term management strategies can mitigate many associated challenges. The disease primarily affects hemoglobin, the molecule responsible for oxygen delivery to cells throughout the body. Hemoglobin S, an aberrant hemoglobin variant, is pivotal in distorting red blood cells into the characteristic sickle or crescent shape. The underlying cause of sickle cell disease lies in a mutation within the hemoglobin-Beta gene located on a chromosome.
“Sickle Cell Disease Pipeline Insight, 2024” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Sickle Cell Disease Market.
The Sickle Cell Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Sickle Cell Disease Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for the treatment of Sickle Cell Disease and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Sickle Cell Disease market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
Sickle Cell Disease (SCD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Intranasal
-
Intrathecal
-
Intravenous
-
Oral
-
Oral/Intravenous
-
Parenteral
-
Subcutaneous
-
Subcutaneous/Intramuscular
-
Transdermal
Molecule Type
Products have been categorized under various Molecule types, such as
-
Antisense oligonucleotide
-
Gene therapy
-
Hormones
-
Neuropeptides
-
Oligonucleotides
-
Small Molecule
-
Triglyceride
Learn How the Ongoing Clinical & Commercial Activities will Affect the Sickle Cell Disease Therapeutic Segment @ https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight
Sickle Cell Disease Therapeutics Landscape
There are approx. 40+ key companies developing therapies for Sickle Cell Disease (SCD). Currently, Vertex Pharmaceuticals is leading the therapeutics market with its Sickle Cell Disease (SCD) drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Sickle Cell Disease (SCD) Therapeutics Market Include:
Agios Pharmaceuticals, Alfasigma, Aruvant Sciences, bluebird bio, Cellectis, CSL Behring, Editas Medicine, ExCellThera, Forma therapeutics, Gamida Cell, Global Blood Therapeutics, Inc., Graphite Bio, KM Biologics, Novartis, Novo Nordisk, Pfizer, Sana Biotechnology, Takeda, Vertex Pharmaceuticals, and many more.
Sickle Cell Disease (SCD) Emerging and Marketed Drugs Covered in the Report Include:
-
BPX-501 T cells: Bellicum Pharmaceuticals
-
Canakinumab: Novartis
-
EPI01: Novo Nordisk
-
CTX001: Vertex Pharmaceuticals
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight
Table of Contents
1. Report Introduction
2. Executive Summary
3. Sickle Cell Disease Current Treatment Patterns
4. Sickle Cell Disease – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Sickle Cell Disease Late Stage Products (Phase-III)
7. Sickle Cell Disease Mid-Stage Products (Phase-II)
8. Sickle Cell Disease Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Sickle Cell Disease Discontinued Products
13. Sickle Cell Disease Product Profiles
14. Key Companies in the Sickle Cell Disease Market
15. Key Products in the Sickle Cell Disease Therapeutics Segment
16. Dormant and Discontinued Products
17. Sickle Cell Disease Unmet Needs
18. Sickle Cell Disease Future Perspectives
19. Sickle Cell Disease Analyst Review
20. Appendix
21. Report Methodology
Download Sample PDF to Explore the Key Offerings of the Report @ https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Sickle Cell Disease Pipeline Insights 2024 | Clinical Trials, Latest Approvals, Treatment Outlook, Competitive Landscape, Companies | Novartis, Agios Pharmaceuticals, Forma therapeutics, Vertex Pharma